In our first article we addressed the modern challenges to strategic planning; the growing complexity and uncertainty that presents challenges to creating a comprehensive and coherent vision of the
This article is the first in a series of three from Osprey Health Consulting that address the contemporary challenges facing strategic brand planners dealing with increasingly complex and uncertain
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh